PMID- 37097674
OWN - NLM
STAT- MEDLINE
DCOM- 20230427
LR  - 20230427
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 5
DP  - 2023 May
TI  - Long-term Outcomes After Moderate Hypofractionated Proton Therapy for Centrally 
      Located Non-small Cell Lung Cancer.
PG  - 2003-2013
LID - 10.21873/anticanres.16361 [doi]
AB  - BACKGROUND/AIM: To investigate the outcomes of patients with centrally located 
      non-small-cell lung cancer (NSCLC) treated with proton beam therapy (PBT) using 
      moderate hypofractionation. PATIENTS AND METHODS: Between 2006 and 2019, 34 
      patients with centrally located T1-T4N0M0 NSCLC who received moderate 
      hypofractionated PBT were retrospectively reviewed. RESULTS: The median follow-up 
      was 50.8 months (range=5.8-100.4 months). The 3-year overall survival, 
      progression-free survival (PFS), and local control rates were 70.4%, 55.5% and 
      80.5%, respectively. Grade 2 or 3 lung adverse events (AEs) after PBT were 
      observed in five (14.7%) patients; however, grade 3 radiation pneumonitis was 
      observed in one (2.9%) patient. Notably, no grade 4 or higher AEs were observed. 
      Regarding the correlation between the lung dose and proximal bronchial tree 
      maximum dose and grade 2 or higher lung AEs, a weak correlation was observed 
      between the mean lung dose and AEs (p=0.035). Although the clinical target volume 
      (CTV) was a risk factor for poor PFS, no significant correlation was found 
      between the CTV and lung AEs after PBT. CONCLUSION: Moderate hypofractionated PBT 
      may be a useful radiotherapy method for centrally located cT1-T4N0M0 NSCLC.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Nakamura, Masatoshi
AU  - Nakamura M
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan; nakamura@pmrc.tsukuba.ac.jp.
FAU - Ishikawa, Hitoshi
AU  - Ishikawa H
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
AD  - QST Hospital, National Institutes for Quantum Science and Technology, Chiba, 
      Japan.
FAU - Ohnishi, Kayoko
AU  - Ohnishi K
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
AD  - Department of Radiology, School of Medicine, International University of Health 
      and Welfare, Narita, Japan.
FAU - Baba, Keiichiro
AU  - Baba K
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
FAU - Sumiya, Taisuke
AU  - Sumiya T
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
FAU - Murakami, Motohiro
AU  - Murakami M
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
FAU - Hiroshima, Yuichi
AU  - Hiroshima Y
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
FAU - Mizumoto, Masashi
AU  - Mizumoto M
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
FAU - Okumura, Toshiyuki
AU  - Okumura T
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
FAU - Sakurai, Hideyuki
AU  - Sakurai H
AD  - Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, 
      Tsukuba, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Lung Neoplasms
MH  - *Proton Therapy/adverse effects/methods
MH  - Retrospective Studies
MH  - Lung
OTO - NOTNLM
OT  - Proton beam therapy
OT  - centrally located
OT  - dose volume histogram
OT  - moderate hypofractionation
OT  - non-small cell lung cancer
OT  - radiation pneumonitis
EDAT- 2023/04/25 17:42
MHDA- 2023/04/27 06:42
CRDT- 2023/04/25 11:33
PHST- 2023/02/07 00:00 [received]
PHST- 2023/02/20 00:00 [revised]
PHST- 2023/02/24 00:00 [accepted]
PHST- 2023/04/27 06:42 [medline]
PHST- 2023/04/25 17:42 [pubmed]
PHST- 2023/04/25 11:33 [entrez]
AID - 43/5/2003 [pii]
AID - 10.21873/anticanres.16361 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 May;43(5):2003-2013. doi: 10.21873/anticanres.16361.